|Pricing Data (As of market close 01/19/17)|
|Closing Market Price||$22.63|
|Trading Volume (Shares)||6,000|
|Yield & Expenses|
Distribution Yield at NAV
|30 Day SEC Yield|
(As of 12/31/16)
|Total Net Assets|
(As of 1/19/17)
|Annual Expense Ratio |
Morningstar (As of 12/31/2016)
|US Fund Health|
|Intraday Value (IOPV)||SLIMIV|
|Primary Benchmark||Solactive Obesity Index|
|Index Provider||Solactive AG|
Worldwide, more than 10% of men and some 14% of women are now classified as obese; those numbers are predicted to climb to 18% of men and 21% of women by 2025.
Source: World Health Organization, Washington University School of Medicine, NCD Risk Factor Collaboration 4/2016
As obesity and overweight levels rise, so do the enormous direct and indirect medical expenditures for treatment and prevention which globally are estimated at $2 trillion annually – creating increased pressure to tackle the issue.
Source: National Center for Weight & Wellness at George Washington University and the McKinsey Global Institute 4/2015.
The strategy provides investors with the opportunity to invest in companies globally that could benefit as they fight the global obesity epidemic.